Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Australian Clinical Labs Ltd ( (AU:ACL) ) has shared an update.
Australian Retirement Trust Pty Ltd has notified Australian Clinical Labs Limited that it has ceased to be a substantial shareholder in the company as of 21 January 2026, according to a change in relevant interests disclosed under the Corporations Act. The move indicates a reduction in Australian Retirement Trust’s voting power below the substantial holding threshold, signalling a shift in the company’s institutional investor base that may alter its shareholder dynamics but does not, on its own, imply any change to underlying operations.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Limited is an Australian pathology services provider operating clinical laboratories and collection centres, supplying diagnostic testing services to healthcare providers, hospitals and patients across Australia.
Average Trading Volume: 609,283
Technical Sentiment Signal: Sell
Current Market Cap: A$494M
Find detailed analytics on ACL stock on TipRanks’ Stock Analysis page.